Loading...
Inventiva S.A.
IVEVF•PNK
Healthcare
Biotechnology
$2.28
$0.00(0.00%)

Over the past four quarters, Inventiva S.A. demonstrated steady revenue growth, increasing from $1.90M in Q2 2023 to $2.73M in Q2 2024. Operating income reached -$52.25M in Q2 2024, maintaining a consistent -1911% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$51.82M, reflecting operational efficiency. Net income rose to -$49.03M, with EPS at -$0.94. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan